Abstract: Provided is a method of measuring at least one kind of hemoglobin, selected from abnormal hemoglobin, or hemoglobin that is a marker for thalassemia, the method comprising: performing high-performance liquid chromatography, using: an eluent L that contains a phosphoric acid monohydrogen dialkali metal salt (component 1) and a phosphoric acid dihydrogen monoalkali metal salt (component 2) as components, and that has a content of component 1 of from 0.08% by mass to 0.50% by mass with respect to a total mass of the eluent L, a content of component 2 of from 0.04% by mass to 1.2% by mass with respect to a total mass of the eluent L, and a ratio of component 2/component 1 of from 0.4 to 10.

Abstract: In an embodiment, a method for manufacturing a thin layer chromatography (“TLC”) plate is disclosed. The method includes forming a layer of elongated nanostructures (e.g., carbon nanotubes), and at least partially coating the elongated nanostructures with a coating. The coating includes a stationary phase and/or precursor of a stationary phase for use in chromatography. At least a portion of the elongated nanostructures may be removed after being coated. Embodiments for TLC plates and related methods are also disclosed.

Abstract: An apparatus and method for measuring hydrogen peroxide concentration in water to an accuracy of 0.1 ppm comprises a colorimetric assay method to determine hydrogen peroxide concentration. The assay is monitored spectophotometrically at a desired wavelength. Each sample is corrected relative to a control sample and hydrogen peroxide concentration determined with respect to a standard curve.

Abstract: A method and device for locating an emitting source of which measurements of emission propagation at locations different from that of the emitting source can be obtained from those locations, lacking space perception, using a sensor mobile along a self-generated path. After having obtained an emission propagation measurement from the mobile sensor at the mobile sensor location, a free energy variation for moving the sensor from its current location to each of plural possible next locations of the mobile sensor is computed, the free energy being computed as a function of a standardized projected probability field of the location of the diffusing source based on previous emission propagation measurements obtained along the self-generated path. A minimum free energy variation value amongst the computed free energy variations is determined and the location associated with the determined minimum free energy variation is identified as being the next location of the sensor.

Abstract: A sensitive, compact detector measures total reactive nitrogen (NOy), as well as NO2, NO, and O3. In all channels, NO2 is directly detected by laser diode based cavity ring-down spectroscopy (CRDS) at 405 nm. Ambient O3 is converted to NO2 in excess NO for the O3 measurement channel. Likewise, ambient NO is converted to NO2 in excess O3. Ambient NOy is thermally dissociated at 700C to form NO2 or NO in a heated quartz inlet. Any NO present in ambient air or formed from thermal dissociation of other reactive nitrogen compounds is converted to NO2 in excess O3 after the thermal converter. The precision and accuracy of this instrument make it a versatile alternative to standard chemiluminescence-based NOy instruments.

Abstract: An explosive detection apparatus capable of maintaining high availability even in an environment containing a large amount of foreign substances is achieved. The explosive detection apparatus includes means for sequentially replacing a plurality of collection thermal vaporization filters 2 for collecting, heating, vaporizing particles, which have been prepared in advance. The explosive detection apparatus also includes a preheating unit 52 for preheating an unused filter, and sealing is performed by a seal portion between the plurality of filters.

Abstract: An apparatus for surveying includes at least one survey cable, each survey cable having a proximal end attached to a mother vessel, a distal end connected to at least one subsurface towing vessel, and at least one survey device connected to the survey cable between the proximal end and the distal end. The survey cable extends in a direction perpendicular to a longitudinal axis of the mother vessel during a survey. The survey cables extend a distance E sideways from the mother vessel, for example under an ice cap, e.g. solid ice or ice floes. When surveying in a polar region, the mother vessel needs only to break a narrow channel in order to survey a large area, thus saving energy, time and money.

Abstract: A test device including a closeable cavity and a water flow groove with a water transmission channel existing between the water flow groove and the internal part of the cavity. The water flow groove includes a water inlet and a water outlet with the depth of the water inlet being greater than the depth of the water outlet. Simultaneously, side lead-in pipe of drain pipe and elbow pipe on side wall of water inlet pipe are consistent with height of top surface of the ceramic plate, making hydraulic pressure of tested soil sample being zero during dehydrating and soaking process capable of ensuring accuracy of test result. A necking design is applied to reduce water evaporation in the drainage pipe and lower the test errors. Side lead-in pipe is connected with drainage pipe for smoothly draining water and also can prevent air reversely flowing and entering into the base.

Abstract: Disclosed are fibers which contain identification fibers. The identification fibers can comprise one or more chemical markers, or taggants, which may vary among the fibers or be incorporated throughout all of the fibers. The disclosure also relates to the method for making and characterizing the fibers. Characterization of the fibers can include identifying chemical markers and correlating the chemical markers and a taggant chemical marker amounts of at least one of the chemical markers to manufacturer-specific taggants to determine supply chain information. The supply chain information can be used to track the fibers from manufacturing through intermediaries, conversion to final product, and/or the consumer.

Abstract: A dispensing device for holding and dispensing strip-like objects, like test strips for analyzing a sample of bodily fluid, wherein the dispensing device holds a stack of strips. The dispensing device includes a container portion for holding the stack of strips and a dispenser portion for dispensing strips from the dispensing device, one at a time. The dispenser portion includes a movable element for applying a rotation motion to a strip to be dispensed from a first orientation, in which the strip is enclosed in the dispensing device, to a second orientation, in which the strip is at least partially exposed.

Abstract: A compensated patch-clamp system for polynucleotide sequencing and other applications.

Abstract: A diagnostic device is provided that comprises a light source for transmitting a light beam through a blood sample to a light detector, and a permanent magnet, wherein one of the permanent magnet and blood sample is automatically movable relative to the other between a “HIGH” magnetic state position and a “LOW” magnetic state position, such that a substantially high magnetic field is applied to the blood sample causing any hemozoin in the blood sample to tend toward perpendicular orientation to the substantially magnetic field and the suppression, or enhancement of light based on its polarization, and a zero-to-near-zero magnetic field is applied to the blood sample causing the randomization of any hemozoin in the blood sample and a baseline amount of light to pass through the blood sample in the “LOW” magnetic state position.

Abstract: Fluorescence chromophores such as phenylene diamine derivatives can undergo oxidative coupling and polymerization to form optical, colorimetric and fluorogenic, multimers and polymers. The presence of carbonyl containing moieties such as aldehydes and ketones under favorable environmental conditions can initiate, catalyze, accelerate and modulate this reaction which in turn provides a mechanism for the detection and quantitation of such moieties. Selected phenylene diamine derivatives can be used for the detection and quantitation of aldehyde and ketones via measurement of the reaction and the associated spectroscopic transformation. In particular, the use of meta-phenylene diamine (mPDA) and related compounds for aldehyde detection and quantitation is described. The method provides a convenient means for monitoring aldehyde and ketone levels without use of separation steps. The method is applicable to kinetic and quasi-endpoint detection assay formats.

Abstract: An analysis cartridge the includes a main body portion and a filter assembly. The main body portion includes an upper portion that defines an upper chamber and a lower portion that defines a fluid chamber. The filter assembly is movable along a filter assembly path between a first position and a second position. The filter assembly has an opening defined therethrough. In the first position, the opening partially defines the upper chamber and in the second position the opening partially defines the fluid chamber.

Abstract: The present invention can be described as an apparatus and cartridge for detecting the presence of an analyte in a fluid. The invention can also be described as a method of detecting the presence of an analyte in a fluid using the apparatus and cartridge. The method comprises the steps of clamping a sensor cartridge into a cartridge receiver of the apparatus, providing fluid to a fluid flow-path of the cartridge, illuminating at least a portion of a sensor, and using a photodetector to detect a change in the optical property of the sensor, wherein the change is caused by the presence or absence of an analyte in the fluid.

Abstract: A cell culture assay device can include: a substrate having a plurality of discrete microfluidic networks and a plurality of wells over the discrete microfluidic networks, each discrete microfluidic network having one or more wells fluidly coupled thereto, the wells extending upward from the discrete microfluidic networks; and a manifold body coupled with the substrate and having at least one fluid conduit pair for each microfluidic network and/or each well, each fluid conduit pair including a fluid inlet conduit and a fluid outlet conduit fluidly coupled to a corresponding microfluidic network and/or well. The substrate can be formed from a substrate base having the microfluidic networks coupled to a well plate having the wells associated with the microfluidic networks.

Abstract: The invention relates to a method for evaluating if a molecule of interest binds or is incorporated in, at least one target tissue comprising visualizing and comparing the distribution of the molecule of interest and of at least one control compound within the target tissue or on the target tissue surface of at least one animal that has previously received the molecule of interest and/or the control compound. Advantageously, the distribution of the molecule of interest is visualized and compared with the distribution of positive and negative compounds using mass spectrometry imaging on the surface of the target tissue.

Abstract: The invention relates to methods for testing the response of spheroids to exposure with therapeutics. Preferably the spheroids are derived from primary isolate biological tissue and/or cell-containing bodily fluid. Further embodiments relate to spheroid sections and arrays including kits suitable for carrying out the method according to the present invention.

Abstract: A method of determining whether an agent is a neuroeffector is disclosed. The method comprises: (a) labeling dopaminergic neurons which are comprised in a mixed population of cells with a fluorescent dopamine analog; (b) measuring a level of fluorescence in the mixed population of cells; (c) exposing the mixed population of cells to the agent; (d) remeasuring a level of fluorescence in the mixed population of cells, wherein a change in the level of fluorescence is indicative of the substance being a neuroeffector.

Abstract: An imaging agent for detecting analytes in an environment includes functionalized nanodiamonds and functionalized magnetic particles that can selectively interact with an analyte. Each functionalized nanodiamond contains at least one color center configured emit light in response to illumination. At least one property of the light emitted by the color centers is related to the proximity of the functionalized magnetic particles to the color centers. This property can be detected to determine that the functionalized nanodiamonds are proximate to the functionalized magnetic particles, to determine that the functionalized nanodiamonds and the functionalized magnetic particles are interacting with the analyte, or other applications. Devices and methods for detecting properties of the analyte by interacting with the functionalized nanodiamonds and functionalized magnetic particles are also provided.

Abstract: A preparation element set including an image sensor including a sensor surface, a sensor back surface, and a board; a package including a front surface, a back surface, and terminals on the back surface, the front surface touching or facing the sensor back surface; and a transparent plate facing the sensor surface with a subject placed therebetween, wherein the board includes a board surface and a board back surface, a distance between the board surface and the sensor surface is less than a distance between the board back surface and the sensor surface, a distance between the board surface and the sensor back surface is more than a distance between the board back surface and the sensor back surface, conductive holes pierce the board from the board surface to the board back surface, and conductors on the board surface are electrically connected to terminals by using the conductive holes.

Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.

Abstract: A breath analysis system that includes a handle assembly with an analysis cartridge on an upper end thereof. The handle includes a main body portion with a pressure opening and a pressure transducer therein. The analysis cartridge includes a main body portion with an upper portion that defines a breath chamber, a lower portion that defines a fluid chamber and a filter assembly that is movable between a breath capture position and an analysis position. The filter assembly has an opening defined therethrough. In the breath capture position, the opening partially defines the breath chamber and in the analysis position the opening partially defines the fluid chamber. The system also includes an analysis device with a case, a door, a controller that controls the motor and a fluorescence detection assembly and a rotation assembly positioned in the case interior. The rotation assembly includes a shroud with a funnel portion for receiving the analysis cartridge.

Abstract: Methods of purifying antibody-nanoparticle conjugates with size exclusion chromatography are provided.

Abstract: The invention provides for the labeling of antibodies with a fluorescent label, using a solid support comprising an affinity for an Fc portion of an antibody. Thus, the invention provides a method for labeling an antibody or fragment thereof with a fluorescent label, comprising the steps of immobilizing an antibody on the solid support and covalently coupling a fluorescent label to the immobilized antibody, as well as a kit for performing such method.

Abstract: The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Abstract: The invention discloses a reduced thickness membrane matrix for carrying liquids consisting of a cellulosic material with a thickness of between 10 and 50 ?m and a pore size between 0.1 ?m and 20 ?m for use with diagnostic tests such as lateral flow tests, thereby reducing the amount of test reagents required.

Abstract: A microscale method for the characterization of one or more reaction variables that influence the formation or dissociation of an affinity complex comprising a ligand and a binder, which have mutual affinity for each other.

Abstract: The present invention relates to a test system or an assay system (detection system) and test method preferably for use in the Point-of-Care (PoC) field.

Abstract: This invention is in the field of medical devices. Specifically, the present invention provides fluidic systems having a plurality of reaction sites surrounded by optical barriers to reduce the amount of optical cross-talk between signals detected from various reaction sites. The invention also provides a method of manufacturing fluidic systems and methods of using the systems.

Abstract: Assays, kits, methods, and devices for diagnosing or predicting the likelihood of occurrence preeclampsia in a subject are disclosed.

Abstract: Analytical immunosensor device and method for obtaining thereof based on sequential deposition of self-assembled monolayers of polymers and affinity elements and their uses for the detection and quantitation of any analyte or target antigen in a liquid sample, allowing to perform the analysis by quasi-reagentless or reagentless displacement assay, and minimizing nonspecific adsorption and thus decreasing the detection limit. The device is arranged from a sensor surface covered with polymer monolayers (redox or non-redox) on top of which submonolayers of affinity elements are deposited and then, to let the affinity reaction to take place with the antigen, pseudo-antigen or the hapten labelled with a protein, preferably an enzyme (redox or non-redox), or with a nanoparticle enabling the method of the invention to develop “ad hoc” immunosensors, with a signal transduction by electrochemical, optical and/or piezoelectric means.

Abstract: One aspect of the invention provides a device for detecting an analyte in a sample. The device includes: a sample loading region, an imaging window, a well, and an absorbent pad. The sample loading region is in fluid communication with the well. The well is in fluid communication with the absorbent pad, such that when a fluid sample comprising solid support structures and a liquid carrier are applied to the sample loading region, the fluid sample travels to the well and at least part of the liquid carrier is absorbed into the absorbent pad.

Abstract: Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (AQP4), binding of which to AQP4 causes the autoimmune disease, Neuoromyelitis Optica. Methods of generating peptoid libraries and for diagnosing Neuromyelitis Optica are also provided.

Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.

Abstract: Embodiments of various aspects described herein are directed to methods, compositions, kits and systems for detecting and/or capturing a target entity in a sample. In particular, the methods, compositions and kits described herein relate to pretreatment of target-binding agents with a blocking agent described herein to reduce non-target binding in a complex matrix (e.g., blood). In some embodiments, methods and compositions for detecting and/or capturing a microbe in a test sample, including bodily fluids such as blood and tissues of a subject, food, water, and environmental surfaces are also provided herein.

Abstract: Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient.

Abstract: Provided herein are biomarkers of acute liver injury (ALI), which includes acute liver failure, and methods of diagnosing ALI and/or monitoring treatment and prognosis therewith. In particular, serum levels of carbamoyl phosphate synthatase-1 (CPS1) are detected to diagnose and/or monitor treatment and prognosis of ALI.

Abstract: The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.

Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.

Abstract: Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof.

Abstract: This disclosure relates to a method to mimicking the germinal center reaction to generate antibodies with altered binding properties or increased affinity directly in hybridomas. To allow convenient and rapid affinity maturation of antibodies, a controllable activation-induced cytidine deaminase (AID) expression system to induce somatic hypermutation in hybridomas is developed. Selection of high affinity antibodies is achieved by fluorescence-activated cell sorting of hybridomas that preferentially bind fluorescence-labeled antigens. The disclosure also relates to de novo generation of hybridomas with tunable antibody affinity by generating myeloma fusion partners with controllable AID expression.

Abstract: In particular the present invention relates to a method for predicting the risk of relapse and distant metastasis in a patient suffering from a triple negative breast cancer comprising the step of i) determining the level of soluble CD95L in a blood sample obtained from the patient ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that the patient will exhibit an increased risk of relapse and distant metastasis when the level determined at step i) is higher than the predetermined reference value or concluding that the patient will exhibit a decreased risk of relapse and distant metastasis when the level determined at step i) is lower than the predetermined reference value.

Abstract: Provided are methods and kits for the use of galectin-3, alone or in combination with prostate specific antigen (PSA), as a marker for the presence or absence of and/or activity of prostate cancer.

Abstract: The present invention relates generally to a method for detecting an aberrant cell, and more particularly an apoptotic cell, in a subject or in a biological sample from said subject, and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting an apoptotic cell by detecting the presence of extranuclear nuclear molecules, in particular La, or a relative increase in extranuclear nuclear molecule levels. The present invention further provides a method for diagnosing or monitoring conditions characterised by aberrant, unwanted or otherwise inappropriate cellular apoptosis in a subject or in a biological sample from said subject by screening for up-regulation of extranuclear nuclear molecule levels in a cell or group of cells.

Abstract: The present invention relates to methods and kits for predicting the survival time of a patient suffering from a diffuse large B-cell lymphoma (DLBCL). In particular, the present invention relates to a method for predicting the survival time of a patient suffering from a diffuse large B-cell lymphoma (DLBCL) comprising the step of i) determining the level of sPD-L1 in a blood sample obtained from the patient ii) comparing the level determined at step i) with a predetermined reference value and iii) concluding that the patient has a poor prognosis when the level determined at step i) is higher than the predetermined reference value or concluding that the patient has a good prognosis when the level determined at step i) is lower than the predetermined reference value.

Abstract: The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers.

Abstract: Provided are high-throughput detection systems. The systems include a magnetic sensor device, a magnetic field source and a reservoir plate that includes a plurality of fluid reservoirs. The magnetic sensor device includes a support with two or more elongated regions each having a magnetic sensor array disposed at a distal end. Also provided are methods in which the subject high-throughput detection systems find use.

Abstract: The present invention includes a stabilized curcumin composition. The composition includes a curcumin composition and a phosphate composition, wherein the phosphate composition is non-buffering and is provided in an amount sufficient to stabilize and/or prevent the degradation of curcumin and/or a curcuminoid in a biological sample.

Abstract: A handheld diabetes manager is presented with an improved graphical user interface for a bolus calculator. The bolus calculator is configured to receive blood glucose measurements from a blood glucose measurement module and operates, in response to an input, to compute an insulin recommendation for a patient based in part on the blood glucose measurements. The graphical user interface for the bolus calculator includes a health adjustment screen that enables a user to input a value for health events associated with the insulin recommendation, where the input value represents a cumulative effect of the health events on insulin of the patient and the health adjustment screen presents a different icon for each of the health events associated with the insulin recommendation.